Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2011: 106/3 (Sep) pp. 389–565
Pages: 405-415

Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

C. E. Mahan (1), M. T. Holdsworth (1), S. M. Welch (2), M. Borrego (1), A. C. Spyropoulos (3)

(1) University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA; (2) Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Albuquerque, New Mexico, USA; (3) Department of Medicine, McMaster University, Hamilton, Ontario, Canada


Deep-vein thrombosis, Adverse event, Adverse drug event, cost model, preventable


Preventable venous thromboembolism (VTE) and “appropriate” type, dose, and duration of prophylaxis are emerging concepts. Contemporary definitions by key quality organisations, including the World Health Organization, have shifted towards “preventable” VTE being considered an adverse event or adverse drug event. A decision tree and cost model were developed to estimate the United States health care costs for total deep-vein thrombosis (DVT), total hospital-acquired DVT, and total “preventable” DVT. Annual cost ranges were obtained in 2010 US dollars for total ($7.5 to $39.5 billion), hospital-acquired ($5 to $26.5 billion), and preventable ($2.5 to $19.5 billion) DVT costs. When the sensitivity analysis was applied – taking into consideration higher incidence rates and costs – annual US total, hospital-acquired, and “preventable” DVT costs ranged from $9.8 to $52 billion, $6.8 to $36 billion, and $3.4 to $27 billion, respectively.

You may also be interested in...


C. E. Mahan (1), M. E. Borrego (2), A. L. Woersching (2), R. Federici (3), R. Downey (3), J. Tiongson (3), M. C. Bieniarz (3), B. J. Cavanaugh (3), A. C. Spyropoulos (4)

Thromb Haemost 2012 108 2: 291-302

W. Blättler 1 , H. E. Gerlach2

Phlebologie 2005 34 3: 146-156

Alexander T. Cohen 1, Giancarlo Agnelli 2, Frederick A. Anderson 3, Juan I. Arcelus 4, David Bergqvist 5, Josef G. Brecht 6, Ian A. Greer 7, John A. Heit 8, Julia L. Hutchinson 9, Ajay K. Kakkar 10, Dominique Mottier 1 1, Emmanuel Oger 1 1, Meyer-Michel Samama 1 2, Michael Spannagl13 for the VTE Impact Assessment Group in Europe (VITAE)

Thromb Haemost 2007 98 4: 756-764